These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
217 related articles for article (PubMed ID: 23442925)
1. Recent advances in vaccine development for herpes simplex virus types I and II. Coleman JL; Shukla D Hum Vaccin Immunother; 2013 Apr; 9(4):729-35. PubMed ID: 23442925 [TBL] [Abstract][Full Text] [Related]
8. Towards a rational design of an asymptomatic clinical herpes vaccine: the old, the new, and the unknown. Chentoufi AA; Kritzer E; Yu DM; Nesburn AB; Benmohamed L Clin Dev Immunol; 2012; 2012():187585. PubMed ID: 22548113 [TBL] [Abstract][Full Text] [Related]
9. Developments in herpes simplex virus vaccines: old problems and new challenges. Rajcáni J; Durmanová V Folia Microbiol (Praha); 2006; 51(2):67-85. PubMed ID: 16821715 [TBL] [Abstract][Full Text] [Related]
10. A Herpes Simplex Virus 2 (HSV-2) gD Mutant Impaired for Neural Tropism Is Superior to an HSV-2 gD Subunit Vaccine To Protect Animals from Challenge with HSV-2. Wang K; Goodman KN; Li DY; Raffeld M; Chavez M; Cohen JI J Virol; 2016 Jan; 90(1):562-74. PubMed ID: 26559846 [TBL] [Abstract][Full Text] [Related]
11. Inactivated HSV-2 in MPL/alum adjuvant provides nearly complete protection against genital infection and shedding following long term challenge and rechallenge. Morello CS; Kraynyak KA; Levinson MS; Chen Z; Lee KF; Spector DH Vaccine; 2012 Oct; 30(46):6541-6550. PubMed ID: 22947141 [TBL] [Abstract][Full Text] [Related]
12. Comparison of different forms of herpes simplex replication-defective mutant viruses as vaccines in a mouse model of HSV-2 genital infection. Da Costa XJ; Morrison LA; Knipe DM Virology; 2001 Sep; 288(2):256-63. PubMed ID: 11601897 [TBL] [Abstract][Full Text] [Related]
13. Mechanisms of Immune Control of Mucosal HSV Infection: A Guide to Rational Vaccine Design. Truong NR; Smith JB; Sandgren KJ; Cunningham AL Front Immunol; 2019; 10():373. PubMed ID: 30894859 [TBL] [Abstract][Full Text] [Related]
14. Development of prophylactic vaccines for genital and neonatal herpes. Jones CA; Cunningham AL Expert Rev Vaccines; 2003 Aug; 2(4):541-9. PubMed ID: 14711338 [TBL] [Abstract][Full Text] [Related]
15. Construction and properties of a herpes simplex virus 2 dl5-29 vaccine candidate strain encoding an HSV-1 virion host shutoff protein. Reszka NJ; Dudek T; Knipe DM Vaccine; 2010 Mar; 28(15):2754-62. PubMed ID: 20117270 [TBL] [Abstract][Full Text] [Related]
17. A Herpes Simplex Virus (HSV)-2 Single-Cycle Candidate Vaccine Deleted in Glycoprotein D Protects Male Mice From Lethal Skin Challenge With Clinical Isolates of HSV-1 and HSV-2. Burn C; Ramsey N; Garforth SJ; Almo S; Jacobs WR; Herold BC J Infect Dis; 2018 Feb; 217(5):754-758. PubMed ID: 29216362 [TBL] [Abstract][Full Text] [Related]
18. A Novel High-Intensity Focused Ultrasound-Treated Herpes Simplex Virus 2 Vaccine Induces Long-Term Protective Immunity against Lethal Challenge in Mice. Xiao J; Zhou X; Luo Y; Wang S; Yang Z; Yi Y; Xiong H mSphere; 2020 Dec; 5(6):. PubMed ID: 33361122 [TBL] [Abstract][Full Text] [Related]
19. The dominant-negative herpes simplex virus type 1 (HSV-1) recombinant CJ83193 can serve as an effective vaccine against wild-type HSV-1 infection in mice. Augustinova H; Hoeller D; Yao F J Virol; 2004 Jun; 78(11):5756-65. PubMed ID: 15140973 [TBL] [Abstract][Full Text] [Related]
20. A novel HSV-2 subunit vaccine induces GLA-dependent CD4 and CD8 T cell responses and protective immunity in mice and guinea pigs. Odegard JM; Flynn PA; Campbell DJ; Robbins SH; Dong L; Wang K; Ter Meulen J; Cohen JI; Koelle DM Vaccine; 2016 Jan; 34(1):101-9. PubMed ID: 26571309 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]